Enhancement of Dissolution Rate of Irbesartan by Chitosan based Crystal Engineering Technique

Shete A.S.*, Yadav A.V² and Murthy M.S³

¹Department of Pharmaceutics, Shree Santkrupa College of Pharmacy, Ghogoan, Karad-415111, India
²Gourishankar Institute of Pharmaceutical Education and Research, Limb, Satara- 415002, India
³Vignan Institute of Pharmaceutical Sciences, Deshmukhi – 508284 Nalgonda Dist. India

ABSTRACT

The objectives of present investigations were to enhance dissolution rate of irbesartan by using chitosan and chitosan chloride and optimize an effective concentrations of both. Cocrystals of irbesartan (IB) were prepared by solvent change technique. Chitosan solution was prepared by soaking chitosan and chitosan chloride in glacial acetic acid. A weighed amount of drug was dispersed in chitosan solution by stirring. The dispersion was added to sodium citrate solution to precipitate chitosan on drug crystals. The precipitate obtained was filtered through Whatmann No. 1 filter paper using vacuum filtration unit and dried at 45 °C for 24 h. The prepared cocrystals were characterized in terms of saturation solubility, drug content, infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), in vitro dissolution studies and stability studies. The considerable improvement in the dissolution rate of drug from optimized co-crystal formulation was attributed to the decreased drug crystallinity, altered surface morphology and reduction in particle size. The 0.2% chitosan and 0.4% chitosan chloride were found to be optimized concentrations for enhancement of dissolution rate of irbesartan. The technique is scalable and may prove valuable in manufacturing process in future for enhancement of dissolution of poorly water soluble drugs.

INTRODUCTION

The rate of absorption and bioavailability of poorly water soluble drugs is often controlled by the rate of dissolution of the drug in gastrointestinal tract. Many technological methods of enhancing the dissolution characteristics of slightly water soluble drugs have been reported in literature. These include reducing particle size to increase the surface area, solubilization in surfactant system, formation of water soluble complexes, use of prodrug, drug derivatization and manipulation of solid state of drug substance to improve drug dissolution i.e. by decreasing drug crystallinity or crystal engineering

Co-crystals often rely on hydrogen-bonded assemblies between neutral molecules of API and other component. For nonionizable compounds co-crystals enhance pharmaceutical properties by modification of chemical stability, moisture uptake, mechanical behavior, solubility, dissolution rate and bioavailability.

Chitosan is a linear polycationic copolymer of β (1–4) linked 2-acetamido-2-deoxy-β-D-glucopyranose and 2- amino-2-deoxy-β-D-glucopyranose obtained from deacetylation of chitin, a structural polysaccharide which is abundantly present in animal and plant kingdom.

*Address for Correspondence:
Shete Amol Somanath, Assistant Professor, Dept. of Pharmaceutics, Shree Santkrupa College of Pharmacy, Ghogoan, Tal. Karad Dist. Satara, M.S (INDIA)
E-mail: amol.shete@rediffmail.com
distributed in nature. In recent year’s chitosan and chitosan derivatives have gained increasing interest in the pharmaceutical field due to its favorable biological properties such as biocompatibility, biodegradability, and lack of toxicity, together with its wide availability, low cost and high versatility of use. Previously chitosan was largely used as an excipient for oral drug solid dosage forms, due to its binder, anti-adherent and disintegrant properties.

Chitosan, being cationic polysaccharide in neutral or basic pH conditions, contains free amino group and hence insoluble in water. In acidic ph, amino group can undergo protonations thus making it soluble in water. It breaks down slowly to amino sugars harmless products, which are completely absorbed by the human body. Moreover, its ability in improving the dissolution properties and bioavailability of poorly-soluble drugs has been proved.

Irbesartan 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl) benzyl]-1, 3-diazaspiro [4.4] non-1-en-4-one, is slightly soluble in alcohol and methylene chloride and practically insoluble in water. Compounds with aqueous solubilities lower than 0.1 mg/ml often represents dissolution rate limited absorption. The irbesartan is available in three dose strengths 75, 150 and 300 mg tablets. The estimated bioavailability is greater than 60%, however plasma levels do not increase proportionally with dose. The calculated biopharmaceutical parameters suggested that IBS has absorbable dose of 26 mg, which is far lower than lowest dose of the drug. Also the volume of aqueous medium required to dissolve the highest dose, calculated using the ratio of dose/ solubility was 20 L. Thus theoretically IB exhibits a solubility limited bioavailability and would be advantageous to enhance the solubility and dissolution rate of IBS. The solid systems for several drugs using chitosan have been reported with solid dispersions, co-ground mixtures and solid complexes, physical mixture and co-ground products and spray dried products at different ratios. There are hardly any reports on the improvement of dissolution rate and bioavailability of poorly water soluble drugs by precipitation of chitosan using solvent change method. Hence objectives of present study were (i) to assess the feasibility of chitosan and chitosan chloride in enhancing dissolution rate of irbesartan by preparing co-crystals using solvent change method. (ii) To compare efficacy of low molecular weight chitosan (chitosan chloride hydrate) and chitosan in enhancement of dissolution rate of irbesartan.

MATERIALS AND METHODS

Irbesartan was obtained as gift sample from Alembic Pharma. Pvt. Ltd. Vododra. India. Chitosan (85% deacetylated), chitosan chloride obtained from mehtani chitosan India. Hydrochloric acid (35-38%), glacial acetic acid (99.5%), sodium citrate (99.5%) was purchased from Loba chemicals, Mumbai, India. All other chemicals were of analytical grade.

Preparation of Co-crystals:

The composition of different formulations is given in table 1. Chitosan solution was prepared by soaking chitosan and chitosan chloride hydrate in 1% glacial acetic acid for 3 h. A weighed amount of drug was dispersed in chitosan solution by stirring at 4000 rpm for 25 min. The dispersion was added to sodium citrate solution to precipitate chitosan on drug crystals. The precipitate obtained was filtered through Whatmann No. 1 filter paper using vacuum filtration unit and dried at 45°C for 24 h. The dried product then passed through sieve No. 60 to obtain uniform size distribution. A control crystal formulation without chitosan was also prepared (C12). The practical yield of prepared crystals was calculated.

Solubility, Drug Content Determination:

An excess amount of irbesartan or prepared cocrystals was placed in the vials containing 10 ml of different solvents (water and 0.1 N HCl) the vials were agitated in an incubator shaker (100 rpm/ min) for 24 hrs at room temperature. The solution was filtered through a membrane (0.45 μm) the amount of drug solublized was analyzed spectrophotometrically (SHIMADZU, 1700, Japan) at 244 nm. This study was carried to determine the saturation solubility of irbesartan in water and 0.1 N HCL.

For determination of drug content, prepared cocrystals (10mg) were triturated with 0.1 N HCL and finally volume was made upto 100 ml with the same. The solution was filtered through a membrane (0.45 μm) the amount of drug

| Table 1: Composition of irbesartan-chitosan and chitosan chloride hydrate co crystals formulations |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Batch code     | Irbesartan (mg) | Chitosan (%)    | Chitosan chloride hydrate (%) | Glacial acetic acid (ml) | Sodium citrate (2%) |
| C1             | 500             | 0.05            | -                            | 20                           | 100                  |
| C2             | 500             | 0.2             | -                            | 20                           | 100                  |
| C3             | 500             | 0.4             | -                            | 20                           | 100                  |
| C4             | 500             | 0.6             | -                            | 20                           | 100                  |
| C5             | 500             | 0.8             | -                            | 20                           | 100                  |
| C6             | 500             |                | 0.05                         | 20                           | 100                  |
| C7             | 500             |                | 0.2                          | 20                           | 100                  |
| C8             | 500             |                | 0.4                          | 20                           | 100                  |
| C9             | 500             |                | 0.6                          | 20                           | 100                  |
| C10            | 500             |                | 0.8                          | 20                           | 100                  |
| C11            | 500             |                | 1                            | 20                           | 100                  |
| C12            | 500             |                | 2                            | 100                          | 200                  |
solublized was analyzed spectrophotometrically (SHIMADZU, 1700, Japan) at 244 nm after sufficient dilutions with 0.1 N HCL.

Infrared (IR) Spectroscopy:
IR spectroscopy was conducted using a Shimadzu FTIR 8300S Spectrophotometer (Shimadzu, Tokyo, Japan) and the spectrum was recorded in the wavelength region of 4000–400 cm⁻¹. The procedure consisted of dispersing a sample (drug alone, mixture of drug and polymer or prepared co-crystals) in KBr and compressing into discs by applying a pressure of 5 t for 5 min in a hydraulic press. The pellet was placed in the light path and the spectrum was recorded. All spectra were collected as an average of three scans at a resolution of 2 cm⁻¹.

Differential Scanning Calorimetry:
DSC was performed using DSC - SDT Q 600 V20.9 Build 20 (Shimadzu, Tokyo, Japan) calorimeter to study the thermal behavior of drug alone and prepared co-crystals. The samples were heated in hermetically sealed aluminum pans under nitrogen flow (30 ml/min) at a scanning rate of 10 °C/min from 50 °C to 300 °C. Empty aluminum pan was used as a reference. The physical mixture of drug with excipients for compatibility studies was prepared by triturating the drug with excipients in a dried mortar for 5 min.

Powder X-Ray Diffraction (XRD):
The X-ray diffraction patterns of pure drug and the optimized crystals formulation were recorded using Philips analytical X-ray diffractometer (Model: PW 3710) (Philips, Almelo, The Netherlands) with a copper target over the interval of 5-70 ° 2θ. The conditions were: voltage 40 kV; current 30 mA; scanning speed 2°/min; temperature of acquisition: room temperature; detector: scintillation counter detector; sample holder: non-rotating holder.

Scanning Electron Microscopy (SEM):
The surface characteristics of the pure drug and prepared crystals were studied by SEM (JEOL, JSM 50A, Tokyo, Japan) at 1600×. The samples were mounted on double-sided adhesive tape that has previously been secured on copper stubs and then analyzed. The accelerating voltage was 10 kV.

In Vitro Dissolution study:
The dissolution rate of irbesartan alone and prepared cocrystals were measured in triplicate in a dissolution apparatus (Lab India, Model Disso 2000 Tablet dissolution test apparatus, Mumbai, India) using apparatus USP Type II. Dissolution studies were carried out using 900mL 0.1 N HCl at 37 ± 0.5°C at 50rpm. 100 mg irbesartan or its equivalent amount cocrystals were added to 900 mL 0.1N HCl. 5 mL samples were withdrawn after 15, 30, 45, 60 and 90min and replaced each time with 5mL fresh 0.1 N HCL. The solutions were immediately filtered through 0.45 mm membrane filter, diluted and the concentration of irbesartan was determined spectrophotometrically at 244 nm.

Stability study:
After determining the drug content, the optimized crystals were charged for accelerated stability studies as per ICH guidelines. The samples (each 100mg, n=3) were kept for stability studies at 40 ± 2 °C and 75 ± 5% RH for a period of 6 months in environmental test chamber (HMG INDIA, Mumbai). The samples were kept in glass vials sealed with rubber plugs. 10 mg of stored crystals were taken out at 15, 30, 60, 90 and 180 days and analyzed for drug content and physical change.

RESULTS AND DISCUSSION

Practical yield, drug content and solubility:
The solubility, dissolution behavior and permeability of a drug are the key determinants of its oral bioavailability. The solubility data of Irbesartan reveals that it is poorly soluble in water. Therefore, the improvement of irbesartan dissolution from its oral solid dosage forms is of great concern.

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>% Yield</th>
<th>Drug content</th>
<th>Water (mg/ml)</th>
<th>0.1 N HCL (mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Irbesartan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1</td>
<td>86.62</td>
<td>99.23±0.58</td>
<td>0.021±0.001</td>
<td>0.054±0.004</td>
</tr>
<tr>
<td>C2</td>
<td>81.32</td>
<td>99.12±0.76</td>
<td>0.059±0.002</td>
<td>0.076±0.003</td>
</tr>
<tr>
<td>C3</td>
<td>76.86</td>
<td>99.45±0.68</td>
<td>0.063±0.001</td>
<td>1.04±0.001</td>
</tr>
<tr>
<td>C4</td>
<td>65.83</td>
<td>99.78±0.98</td>
<td>0.056±0.004</td>
<td>1.03±0.002</td>
</tr>
<tr>
<td>C5</td>
<td>60.76</td>
<td>98.24±1.23</td>
<td>0.045±0.001</td>
<td>1.04±0.004</td>
</tr>
<tr>
<td>C6</td>
<td>87.86</td>
<td>98.45±0.98</td>
<td>0.021±0.005</td>
<td>0.047±0.004</td>
</tr>
<tr>
<td>C7</td>
<td>83.23</td>
<td>99.14±1.45</td>
<td>0.059±0.003</td>
<td>0.086±0.001</td>
</tr>
<tr>
<td>C8</td>
<td>74.32</td>
<td>99.56±1.02</td>
<td>0.065±0.002</td>
<td>1.05±0.003</td>
</tr>
<tr>
<td>C9</td>
<td>70.46</td>
<td>99.89±1.13</td>
<td>0.16±0.004</td>
<td>1.03±0.002</td>
</tr>
<tr>
<td>C10</td>
<td>64.23</td>
<td>99.25±0.87</td>
<td>0.14±0.005</td>
<td>1.04±0.001</td>
</tr>
<tr>
<td>C11</td>
<td>60.21</td>
<td>98.78±0.96</td>
<td>0.098±0.004</td>
<td>1.05±0.004</td>
</tr>
<tr>
<td>C12</td>
<td>92.32</td>
<td>99.63±1.96</td>
<td>0.014±0.001</td>
<td>0.041±0.004</td>
</tr>
</tbody>
</table>
In the solubility studies of the prepared crystals from chitosan, formulation batch C-3 showed highest solubility of drug in both water (0.063 mg/ml) and 0.1N HCl (1.04 mg/ml) in comparison with pure drug (water: 0.013 mg/ml; 0.1N HCl: 0.043 mg/ml). If we compare solubility data of chitosan and chitosan chlorhydrate batch C9 showed better aqueous solubility (0.16 mg/ml). No difference was observed in case of solubility in 0.1 N HCL. The difference in aqueous solubility of chitosan and chitosan chlorhydrate may be due to better wetting property and low molecular weight of chitosan chlorhydrate. In addition, as the concentration of chitosan or chitosan chlorhydrate increased in the formulation, the solubility gradually increased up to a certain concentration followed by decrease in the solubility.

**Infrared (IR) Spectroscopy:**

The possible interaction between drug and chitosan as co-crystal formers were studied by IR spectroscopy as shown in figure 1. The pure irbesartan showed peaks at 1734.06 cm\(^{-1}\), 1616.40 cm\(^{-1}\), 1300-1400 cm\(^{-1}\), 758.05 cm\(^{-1}\) due to presence of C=O, conjugation with double bond, C-N stretch and C-H bending vibrations of aromatic ring respectively. It was observed that all important peaks due to functional group of drug are present in the co crystals along with some new intense peaks indicating the presence of hydrogen bonding. Also there are peaks observed in the range of 400-800 cm\(^{-1}\) in co crystals prepared from chitosan chlorhydrate indicative of halogen hydrogen interaction.

**PXRD:**

The XRD patterns of the pure drug and the co crystals are shown in figure 2. The PXRD scan of plain irbesartan showed intense peak of crystallinity at 12.4° (2θ) with peak intensity of 21123 indicating its crystalline nature. The relative degree
of crystallinity values of irbesartan co-crystals at specific angle are 0.729, 0.514 for 0.2% chitosan and 0.2% chitosan chlorhydrate co-crystals respectively. It indicates decrease in crystallinity of irbesartan in co-crystals.

Differential Scanning Colorimetry:
The results of DSC studies are shown in figure 3. IB showed an endothermic peak at 190.58°C corresponding to its melting point followed by an exothermic peak at 244°C. This exothermic peak might convert the drug into more stable but less soluble form. The peaks of chitosan and chitosan based co-crystals were broad, less sharp than drug, cocrysals also showed exothermic peaks nearer to 244°C. The endothermic peaks of co-crystals were found to be same as that of drug confirming that the resultant co-crystals were in the crystalline state. This was also confirmed from P-XRD and SEM analysis.

Scanning Electron Microscopy (SEM):
The SEM photomicrographs of pure irbesartan and the selected crystal formulations are given in Figure 4. The pure Irbesartan was characterized by crystals of bigger size and regular shape with an apparently smooth surface. In contrast crystals were present in the form of fine powder. Additionally, crystals were fluffy and possess porous and rough surface which might have resulted in the enhanced dissolution rate as compared to pure drug. The size of crystals was comparatively less than that of plain IB, which further supports the results of particle size determination.

In Vitro Dissolution studies:
The results of in vitro drug release studies in 0.1N HCl for 1 h are depicted in Figure 5. The pure drug showed a release of 54.21% at the end of 1 h. The control crystals (without chitosan; C-12) showed 60.45% drug released in 1 hr. various crystals (C1 to C5) were prepared using increasing concentrations of chitosan using sodium citrate (2%) as dispersion medium. The chitosan salted-out with the sodium salts of citric, tartaric, malic and malonic acids was in general more soluble in dilute aqueous HCl or dilute aqueous acetic acid.\cite{17,18} The C-1 crystals containing 0.05% chitosan showed a drug release of 55.14% in 1 h. Crystals C-2 to C-5 was again prepared by increasing the chitosan concentrations. Highest drug release was observed with C-2, C3 crystals with 0.2% and 0.4% chitosan (105.44% and 109.4% in 1 h). Further with increase in concentration of chitosan C4, C5 decrease in drug release was observed compare to C2. It was interesting to note that chitosan was able to increase the dissolution rate at lower concentrations when associated with sodium citrate. This could be due to efficient adsorption of chitosan on drug particles in the presence of sodium citrate. It has been reported that polymers with positively or negatively charged groups interact with molecules of opposite charges to form three dimensional networks. The reaction of chitosan with multivalent anions like sodium citrate (anion cross-linker) allows the formation of bridges between the polymeric chains and results in cross-linking (by electrostatic interaction) between the chitosan molecules, which might have eventually resulted in efficient adsorption of chitosan on drug particles.
Cocrystals prepared by using chitosan chlorhydrate showed better drug release than chitosan this might be due to the water soluble nature of chitosan chlorhydrate (figure 6). The crystals prepared by chitosan showed release (C2 and C3) 47.88, % and 43.82% at the end of 15 min. The crystals (C7 and C8) showed 100.1% and 78.72% drug release in 15 min.

The increase in the irbesartan solubility, although little, and significant increase in its dissolution rate from prepared crystals can be explained as following: Chitosan has been proposed as a useful excipient for enhancing the bioavailability of poorly water-soluble compounds. Chitosan and its derivatives have been reported as a good vehicle for enhancing the solubility and dissolution of poorly water-soluble21-23. Chitosan dissolves readily in most of the acid solutions and upon dissolution, amine groups of the polymer become protonated, resulting in a positively charged polysaccharide (RNH3+) and chitosan salts (chloride, glutamate, etc.) that are soluble in water. The earlier literature reveals that dissolution rate not only depends on the surface area and particle size of the process powder, but is greatly affected by crystal morphology and wettability. So increased wettablility of the drug by the adsorption of chitosan and chitosan chlorhydrate onto the hydrophobic surface of the drug is the first reason. In a previous study also, chitosan showed increased solubility and dissolution rate of naproxen due to adsorption on its surface. As the concentration of polymer is increased dissolution rate was decreased (C-4, C-5, and C7). This could be due to the formation of thick gel layer of the chitosan on the surface of the crystals.

The difference in dissolution rate enhancement by chitosan and chitosan chlorhydrate can be explained as, the trend found was that for the two types of chitosan (base and salt), the lower the Mw, the faster was the drug dissolution. This behavior was predictable taking into account the relationship between Mw and viscosity of polymer solution. Upon contact with the acidic medium; chitosan swells and forms a gel. The diffusion of the drug through the gel into the release medium would be retarded by increasing the viscosity of the polymer, and hence of the gel. On the other hand, the chitosan chlorhydrate led to faster drug dissolution than chitosan. The explanation to this behavior was found in the differences in the wetting rate, solubilities and swelling capacity of the chitosan and chitosan salts, chitosan chlorhydrate rapidly wet and dissolve upon its incorporation into the dissolution medium, whereas the chitosan base being less water soluble, would take more time to dissolve.

In order to clarify the causes of significant difference in the dissolution rate, the surface morphology of the crystals was examined by SEM. Thus the fine and fluffy physical state of crystals along with their porous and rough surface as supported by SEM photomicrographs might also have contributed to the enhanced solubility and dissolution rate of irbesartan from these crystals.

**Stability studies:**

The physical stability of co-crystals was compared with the drug. The co-crystals were found to be stable during the study period as no any change in color was found. The drug content in all the co-crystals was found to be within the limit. The drug content within the formulations is shown in the table 3.

**CONCLUSIONS**

The present study investigated a successful and simple method to prepare irbesartan-chitosan and irbesartan – chitosan chlorhydrate crystals to enhance its dissolution rate. The prepared crystals also exhibited exceptional stability. If this process can be scaled-up to manufacturing level, this technique has the potential to develop into valuable technology in future.

**REFERENCES**

7. Shete A.S et al Enhancement of Dissolution Rate of Irbesartan by Chitosan based Crystal Engineering Technique


*******